제테마
Financials
Valuation Metrics
제테마's Market Cap is ₩2185B. At end of 2025 it was ₩2282B. Ranked #759 of 2,405 in KR market (top 32%), #337 of 1,627 on KOSDAQ (top 21%), #83 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 218.50B KRW | KR#759/2,405 Sec#83/231 |
| Revenue | 76.58B KRW | KR#1,565/2,405 Sec#100/231 |
| Net Income | -1.93B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 243.65B KRW | KR#1,157/2,405 Sec#80/231 |
| Net Assets | 80.71B KRW | KR#1,583/2,405 Sec#128/231 |
| Employees | 243 | KR#945/2,405 Sec#81/231 |
| Value | ||
| P/B | 2.71x | KR#2,103/2,405 Sec#165/231 |
| P/S | 2.85x | KR#1,980/2,405 Sec#124/231 |
| EV/EBITDA | 81.80x | KR#1,468/2,405 Sec#96/231 |
| FCF Yield | 2.47% | KR#1,037/2,405 Sec#66/231 |
| Profitability | ||
| ROE | -2.39% | KR#1,704/2,405 Sec#120/231 |
| ROA | -0.79% | KR#1,645/2,405 Sec#113/231 |
| Op. Margin | 5.00% | KR#959/2,405 Sec#72/231 |
| Revenue Growth | 8.79% | KR#957/2,405 Sec#94/231 |
| Financial Health | ||
| Debt Ratio | 201.88% | KR#2,099/2,405 Sec#219/231 |
| Total Debt | 132.44B KRW | KR#642/2,405 Sec#37/231 |
| FCF | 5.39B KRW | KR#881/2,405 Sec#60/231 |
| Cash | 37.55B KRW | KR#884/2,405 Sec#57/231 |
| Current Ratio | 0.79x | KR#1,940/2,405 Sec#190/231 |
| Net Debt/EBITDA | 24.77x | KR#1,402/2,405 Sec#100/231 |
| Performance | ||
| 1Y Return | 0.86% | KR#599/2,405 Sec#32/231 |
| 1M Return | -2.33% | KR#481/2,405 Sec#47/231 |
| From 52W High | -48.05% | KR#1,076/2,405 Sec#77/231 |
| 1Y MDD | -62.81% | KR#1,608/2,405 Sec#131/231 |
| Trading | ||
| Volume | 56,625 shares | KR#883/2,405 Sec#98/231 |
| Trading Value | 328.4M KRW | KR#949/2,405 Sec#109/231 |
| Foreign Own. | 2.84% | KR#1,334/2,405 Sec#121/231 |
| Per Share | ||
| EPS | -52 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,165 KRW | KR#2,042/2,405 Sec#168/231 |
Company Info
Jetema originated in 2009 as a bio research company focused on chitosan-applied DDS development. Through a 2014 merger and the 2015 completion of a filler-exclusive factory, the company entered the medical aesthetic market, successfully venturing into the toxin market in 2024. Jetema actively researches and develops hyaluronic acid fillers, botulinum toxin-based pharmaceuticals, sutures, and lifting threads. The company is expanding its global presence, securing license-out agreements with Brazil (2020) and China (2022), and pursuing export contracts with Thailand and market entry into the US in 2024. Jetema is headquartered in Wonju City, Gangwon-do.